Compare L3Harris Technologies Inc (LHX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Recursion Pharmaceuticals Inc — how do they compare? L3Harris Technologies Inc trades at $277.71 (market cap $52.27B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: L3Harris Technologies Inc is far larger — about 34.2× Recursion Pharmaceuticals Inc's market cap, and L3Harris Technologies Inc pays a 1.78% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| LHX | RXRX | |
|---|---|---|
Market Cap | $52.27B | $1.53B |
Sector | Industrials | Health |
52-Week High | $378.48 | $6.79 |
52-Week Low | $263.09 | $2.84 |
Enterprise Value | $63.03B | $946.50M |
Dividend Yield | 1.78% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
